4,627 reports of this reaction
9.7% of all IMATINIB MESYLATE reports
#1 most reported adverse reaction
DEATH is the #1 most commonly reported adverse reaction for IMATINIB MESYLATE, manufactured by Novartis Pharmaceuticals Corporation. There are 4,627 FDA adverse event reports linking IMATINIB MESYLATE to DEATH. This represents approximately 9.7% of all 47,520 adverse event reports for this drug.
Patients taking IMATINIB MESYLATE who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is moderately reported among IMATINIB MESYLATE users, representing a notable but not dominant share of adverse events.
In addition to death, the following adverse reactions have been reported for IMATINIB MESYLATE:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 4,627 FDA reports for IMATINIB MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 9.7% of all adverse event reports for IMATINIB MESYLATE, making it one of the most commonly reported side effect.
If you experience death while taking IMATINIB MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.